CVS Health Gestione

Gestione criteri di controllo 2/4

CVS Health Il CEO è J. Joyner, nominato in Oct2024, ha un mandato di meno di un anno. possiede direttamente 0.003% delle azioni della società, per un valore di € 2.23M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 6.8 anni.

Informazioni chiave

J. Joyner

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.003%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

J. Joyner (59 yo)

less than a year

Mandato

Mr. J. David Joyner is President, CEO & Director of CVS Health Corporation from October 17, 2024 and served as Executive Vice President from January 30, 2023 to October 17, 2024 and was President of CVS Ca...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Cowhey	Executive VP & CFO	1.1yrs	US$4.58m	0.0028% € 2.0m
Tilak Mandadi	Executive VP of Ventures and Chief Digital	2.3yrs	US$8.88m	0.0032% € 2.2m
Samrat Khichi	Executive VP	1.8yrs	US$11.89m	0.00077% € 531.3k
Prem Shah	Group President	3yrs	US$8.58m	0.0037% € 2.6m
J. Joyner	President	less than a year	Nessun dato	0.0032% € 2.2m
Vijay Patel	Senior Director of Business Development & CVS Health and Partner & Co-Founder	no data	Nessun dato	Nessun dato
James Clark	Senior VP	6yrs	Nessun dato	0.00067% € 462.3k
David Falkowski	Executive VP & Chief Compliance Officer	no data	Nessun dato	Nessun dato
Heidi Capozzi	Executive VP & Chief People Officer	less than a year	Nessun dato	Nessun dato
Joneigh Khaldun	VP & Chief Health Equity Officer	3.1yrs	Nessun dato	Nessun dato
Kyu Rhee	Senior Vice President	no data	Nessun dato	Nessun dato
Gustavo Giraldo	Head of Markets of Healthcare Benefits	2.8yrs	Nessun dato	Nessun dato

2.3yrs

Durata media

55.5yo

Età media

Gestione esperta: Il team dirigenziale di CVS è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
J. Joyner	President	less than a year	Nessun dato	0.0032% € 2.2m
J. Kirby	Independent Director	1.1yrs	US$195.42k	0.00045% € 310.5k
Roger Farah	Independent Chairman	6yrs	US$576.50k	0.00033% € 227.7k
Mary Schapiro	Independent Director	7.5yrs	US$301.50k	0.00094% € 648.6k
Nancy-Ann DeParle	Independent Director	11.2yrs	US$321.50k	0.0025% € 1.7m
Anne Finucane	Independent Director	13.8yrs	US$321.50k	0.0026% € 1.8m
C. Brown	Independent Director	17.7yrs	US$321.50k	0.0097% € 6.7m
Jean-Pierre Millon	Independent Director	17.7yrs	US$321.50k	0.0087% € 6.0m
Alecia DeCoudreaux	Independent Director	9.7yrs	US$301.50k	0.00024% € 165.6k
Fernando Aguirre	Independent Director	6yrs	US$318.17k	0.0028% € 1.9m
Jeffrey Balser	Independent Director	2.2yrs	US$301.50k	0.00058% € 400.2k
Michael Mahoney	Independent Director	less than a year	US$167.50k	0.0011% € 745.2k

6.8yrs

Durata media

67.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CVS sono considerati esperti (durata media dell'incarico 6.8 anni).

CVS Health Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CVS Health Appoints Sreekanth Chaguturu as President, Health Care Delivery

CVS Health Corporation Announces Board Appointments

CVS Health Announces Leadership Appointments

CVS Health Announces CEO Changes

CVS Health Corporation Appoints Heidi Capozzi as Executive Vice President, Chief People Officer, Effective September 9, 2024

CVS Health Corporation, Annual General Meeting, May 16, 2024

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

CVS Health Appoints Sreekanth Chaguturu as President, Health Care Delivery

CVS Health Corporation Announces Board Appointments

Third quarter 2024 earnings released: EPS: US$0.069 (vs US$1.76 in 3Q 2023)

CVS Health Announces Leadership Appointments

CVS Health Announces CEO Changes

CVS Health Reportedly Considers Sale of Its Insurance Business

Upcoming dividend of US$0.67 per share

Second quarter dividend of US$0.67 announced

CVS Health Announces Quarterly Dividend, Payable on November 1, 2024

Adherence Files Lawsuit Against CVS Health and Asembia for Alleged Unauthorized Use of Its Trademarked and Copyrighted Intellectual Property

CVS Health Announces Updated Flu and COVID-19 Vaccinations Now Available at CVS Pharmacy® and MinuteClinic®

CVS Health Corporation Appoints Heidi Capozzi as Executive Vice President, Chief People Officer, Effective September 9, 2024

Second quarter 2024 earnings released: EPS: US$1.41 (vs US$1.48 in 2Q 2023)

CVS Health Corporation Revises Earnings Guidance for the Full Year 2024

CVS Health Corporation Launches First-Of-Its-Kind Initiative to Support Patients Most Vulnerable to Health Impacts of Extreme Weather Events

First quarter dividend of US$0.67 announced

CVS Health Announces Quarterly Dividend, Payable on August 1, 2024

Investor sentiment deteriorates as stock falls 19%

The Law Firms of Kessler Topaz Meltzer & Check, LLP and Carella, Byrne, Cecchi, Brody & Agnello, P.C. Files a Class Action Lawsuit Against CVS Health Corporation and Related Entities for Preventing SilverScript Members from Accessing Certain Generic Medications

First quarter 2024 earnings released: EPS: US$0.88 (vs US$1.67 in 1Q 2023)

CVS Health Corporation Revises Earnings Guidance for the Full Year 2024

Upcoming dividend of US$0.67 per share

CVS Health Corporation, Annual General Meeting, May 16, 2024

CVS Health Corporation to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of US$0.67 announced

Cvs Health Approves Quarterly Dividend on the Common Stock, Payable on May 1, 2024

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Executive VP recently sold €2.1m worth of stock

Full year 2023 earnings released: EPS: US$6.49 (vs US$3.16 in FY 2022)

Upcoming dividend of US$0.67 per share at 3.1% yield

CVS Health Corporation Provides Earnings Guidance for the Year 2023

CVS Health Announces Executive Changes

Robbins Geller Rudman & Dowd LLP and Aqualaw PLC Reaches Settlements in Class Action with Costco Wholesale Corporation, CVS Health Corporation, The Procter & Gamble Company, Target Corporation, Walgreen Co. and Walmart Inc

CVS Health Approves Quarterly Dividend, Payable on February 1, 2024

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media